NetworkNewsBreaks – Mateon Therapeutics, Inc. (MATN) Shares Surge on Positive Initial Data from Phase 1b Study of OXi4503
Shares of Mateon Therapeutics (OTCQX: MATN) are up 26% this morning after the company released preliminary data from its phase 1b dose-ranging study of OXi4503 in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The data show that two of four patients achieved a complete remission after one cycle of treatment. Additionally, there were no dose-limiting toxicities observed in the fifth cohort and OXi4503 continued to have a favorable safety profile. “Every dose of OXi4503 tested in this study has shown encouraging signs of efficacy and a favorable safety profile, with the highest…







